Summary
CVS Health Corporation (CVS) filed an 8-K report on May 18, 2026, detailing the outcomes of its 2026 Annual Meeting of Stockholders held on May 14, 2026. The primary focus of this filing is the shareholder approval of the new 2026 Incentive Compensation Plan (ICP), which will replace the existing 2017 plan for awards granted after May 14, 2026. This plan was overwhelmingly approved by stockholders, signaling confidence in the company's executive compensation strategy moving forward. In addition to the approval of the 2026 ICP, the filing confirms the re-election of all 13 nominated directors for one-year terms. Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026 and approved, on an advisory basis, the compensation of the company's named executive officers. A single stockholder proposal regarding the reduction of the threshold for stockholder action by written consent was not approved.
Key Highlights
- 1Stockholder approval of the 2026 Incentive Compensation Plan (ICP), replacing the 2017 ICP for future awards.
- 2Re-election of all 13 nominees to the Board of Directors for one-year terms.
- 3Ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.
- 4Advisory approval of the compensation for named executive officers.
- 5A stockholder proposal to reduce the threshold for action by written consent was not approved.
- 6A quorum was established with 1,142,802,406 shares of common stock represented.
- 7The 2026 ICP received strong support, with over 1 billion shares voting in favor.